Climb Bio announced a webcast event on May 5, 2026, to spotlight budoprutug, their clinical-stage anti-CD19 monoclonal antibody targeting B-cell mediated immune diseases like primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. The webcast will cover the scientific rationale, ongoing clinical trials, dose selection, and development strategy. Budoprutug has shown promise in early trials and recently completed dosing for a subcutaneous formulation. The event will feature expert insights from Dr. David Jayne of the University of Cambridge. This highlights Climb Bio's progress in developing treatments for immune-mediated diseases with potential commercial opportunities.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
